|
FOR IMMEDIATE RELEASE
BioNJ and Medidata Collaborate to Address Underrepresentation in Clinical Trials Across New Jersey
In a groundbreaking effort to support the recruitment of underrepresented communities in clinical trials across the United States, BioNJ, the life sciences trade association for New Jersey, has engaged Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, to evaluate the demographic representation in trials conducted within New Jersey.
The study analyzed New Jersey’s recruitment performance by comparing it with similar northeastern states — Connecticut, Maryland, Massachusetts and New York — based on comparable demographic, infrastructural and geographical factors. The goal is to provide insights regarding how effectively clinical trial sponsors are achieving ideal demographic representation among participants.
The findings, detailed in a newly published whitepaper entitled "Health Equity in Clinical Trials: New Jersey Participant Demographics," highlights differences in demographic recruitment across these states and identifies key public policy opportunities to pursue more accurate demographic representation according to epidemiological data.
"By determining recruitment disparities and offering solutions for improvement, our hope is that our recommendations within the whitepaper will help to ensure that clinical trials better reflect the populations they aim to serve," said BioNJ’s President and CEO Debbie Hart. "This is crucial for advancing healthcare equity and ensuring that therapeutics are accurately assessed for every community."
The release of "Health Equity in Clinical Trials: New Jersey Participant Demographics" is a key milestone in BioNJ’s Health Equity in Clinical Trials Initiative, launched in 2022. Driven by a commitment to the vision of "Health Equity for All", BioNJ’s Health Equity in Clinical Trials Initiative was created to define concrete issues that can be remedied with impact, identify long-term interventions, support companies to improve equity and access in their clinical trials strategies, benchmark best practices and shape policy.
Clinical trials are the source of every new therapy. They represent a $15.2 billion enterprise in the U.S. alone. Yet for all the promise they represent — and investment they attract – substantial inequities in clinical trial enrollment limit the benefits to society at large, especially for people from historically marginalized groups that are underrepresented in clinical research.
Therefore, the ultimate objective of the BioNJ-Medidata collaboration is to empower recruitment efforts so that every demographic has equal access to the latest biomedical breakthroughs, and that new therapies are accurately evaluated based on their outcomes within the communities they are designed to treat.
Click here to download a copy of "Health Equity in Clinical Trials: New Jersey Participant Demographics".
Join BioNJ and Medidata on November 7 from 12:00 p.m.-1:00 p.m. as they present the findings live from "Health Equity in Clinical Trials: New Jersey Participant Demographics". Click here to register for free.
For more information, contact:
Randi Bromberg
Sr. Vice President, Communications & Marketing
609-890-3158 (O)
609-955-1067 (C)
| 
